Core Insights - NEXGEL, Inc. has announced the distribution of Histasolv®, a leading DAO enzyme supplement in Europe, through its partnership with STADA Arzneimittel AG, targeting the North American market [1][7] - Histasolv® generates over $10 million in annualized revenue and is designed to treat histamine food intolerance, which can lead to various health issues [1][2] - STADA is a prominent player in consumer healthcare, achieving group sales of EUR 3,797.2 million and EBITDA of EUR 884.7 million in 2022 [4] Product Differentiation - Histasolv® features an innovative formulation that allows it to deliver high potency DAO to the lower intestine, enhancing its effectiveness compared to competitors [2] - The product is individually sealed in nitrogen-preserved blister packs, ensuring stability and potency [2] Strategic Partnership - The partnership between NEXGEL and STADA aims to leverage STADA's expertise in histamine management to penetrate the North American market [3][8] - NEXGEL plans to sell Histasolv® direct-to-consumer starting in the third quarter of 2024, aligning with its strategy to disrupt the traditional consumer health industry [2][7] Company Background - NEXGEL specializes in high-water-content hydrogels for healthcare and consumer applications, with a portfolio that includes brands like Silverseal® and Hexagels® [3] - STADA operates under a three-pillar strategy focusing on consumer healthcare products, generics, and specialty pharmaceuticals, with a presence in approximately 120 countries [4]
NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America